Approval date

Generic (Brand name)

Mechanism of action

Indication

Starting dose (Max)

February 2010

Trazodone hydrochloride (Oleptro)

Dual serotonin agonist, serotonin reuptake inhibitor

MDD

150 mg (375 mg) oral

January 2011

vilazodone hydrochloride (Viibryd )

SSRI, 5HT1A receptor partial agonist

MDD

10 mg (40 mg) oral

July 2013

Levomilnacipran (Fetzima)

Norepinephrine & serotonin reuptake inhibitor

MDD

20 mg (120 mg) oral

October 2013

Vortioxetine (Trintellix/ Brintellix)

Serotonin modulator & stimulation

MDD

10 mg (20 mg) oral

July 2015

Brexpiprazole (Rexulti)

Atypical antipsychotic

Adjunctive for MDD

0.5 mg (3 mg)

oral

March 2019

Esketamine nasal spray (Spravato)

NMDA receptor antagonist

Treatment resistant depression

56 mg (84 mg) intranasal

March 2019

Brexanolone (Zulresso)

Allosteric modulator of GABA-A receptors

Postpartum depression

30 mcg/kg/hr (90 mcg/kg/hr) intravenous infusion